

# ACCP Virtual Journal Club Webinars!

## 2025 ACCP Virtual Journal Club Webinar

### Safety, Tolerability & Pharmacokinetics of Oral Doses of the Sirtuin 6 Activator SP-624


Live Session: Tuesday, March 18<sup>th</sup>, 2025, from 12:00 to 1:00 PM ET

On Demand: March 18<sup>th</sup>, 2025 to March 18<sup>th</sup>, 2028

The Journal of Clinical Pharmacology Article: *Phase 1, Single-Center, Double-Blind, Randomized, Placebo-Controlled Studies of the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of the Sirtuin 6 Activator SP-624 in Healthy Adults*

#### **Why is this webinar important to you?**

Learners that complete this webinar will gain knowledge about a First-in-Class drug with a novel mechanism of action. SP-624 (generic name forvisirvat) is a small molecule activator of the sirtuin (SIRT) 6 enzyme. SIRT6 is a NAD<sup>+</sup> dependent histone deacetylase and is believed to be the first activator of the enzyme tested in human clinical trials. It is currently being assessed in a Phase 2b/3 study for the treatment of major depressive disorder. The webinar presents data from single ascending dose and multiple ascending dose studies conducted in healthy male and female subjects. The safety, tolerability and pharmacokinetics after single multiple doses of forvisirvat will be reviewed.



#### **ACPE Accreditation Statement**

The American College of Clinical Pharmacology<sup>®</sup> is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education.

**UAN:** 0665-0000-25-004-L01-P & 0665-0000-25-004-H01-P

**Contact Hours:** 1.0

**Activity Type:** Knowledge-based

**Format:** Live and Home-study

**Target Audience:** 'P'



#### **ACCME Accreditation Statement**

The American College of Clinical Pharmacology<sup>®</sup> is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

#### **ACCME Designation Statement**

The Accreditation Council for Continuing Medical Education designates this journal CE activity for 1 *AMA PRA Category 1<sup>TM</sup>* credit. Physicians should only claim credit commensurate with the extent of their participation in the activity.

#### **Target Audience**

Interprofessional team of Physicians, Pharmacists, PhDs and other health care professionals, including Clinical Pharmacologists and Allied Health Services, who are involved or interested in the dosing of Sirtuin 6 Activator SP-624.

## Learning Objectives

After completing this activity, the learner will be able to:

1. Describe the pharmacokinetics of SP-62;
2. Identify key characteristics of dose estimation via ascending dose response of Sirtuin 6 Activator;
3. Describe the safety assessments based on the adverse events, serious adverse events and treatment emergent adverse events (TEAEs) of Sirtuin 6 Activator;
4. Discuss the use of pharmacokinetics in early drug development.

## Faculty:

Author/Faculty: Greg Rigdon, PhD, Senior Vice President, Scientific Affairs, Arrivo BioVentures LLC

William Wargin, PhD, Pharmacokineticist, Sirtsei Pharmaceuticals Inc

Moderator/Planner: Vatsalya Vatsalya, MD, PgD, MSc, MS, FRSM, FCP, Assistant Professor of Medicine, Univ of Louisville

CE Reviewer: Joseph Ma, PharmD, Professor, Div of Clinical Pharmacy, Univ of California San Diego, Skaggs School of Pharmacy & Pharmaceutical Sciences

All of the relevant financial relationships for these individuals have been mitigated.

## Schedule & Fees

ACCP webinar programs occur several times per year. Registration for the webinars is required but free of charge to all learners.

---

## Helpful Tips

For best audio and visual quality, we recommend viewing the webinar in the Chrome browser. If you do not have Chrome, you may download it [here](#).

Download the article and slide handouts and access the webinar [here](#).